经皮股动脉导管药盒系统介入治疗肝细胞癌的临床应用  

Clinical Application of Percutaneous Intra-arterial Femoral Port-catheter System for Interventional Treatment for Hepatocellular Carcinoma

作　　者：王峻 汤日杰 谭志明 

机构地区：[1]广州市肿瘤医院,510095

出　　处：《实用癌症杂志》2005年第3期293-294,共2页The Practical Journal of Cancer

摘　　要：目的探讨经皮股动脉导管药盒系统介入治疗肝细胞癌的临床疗效及并发症。方法从1999年1月到2001年3月应用经皮股动脉植入导管药盒系统(PCS)对45例肝细胞癌患者进行化疗和碘油栓塞治疗,回顾性分析临床疗效及并发症。结果PCS介入治疗肝细胞癌的有效率为66.7%(30/45)。患者1、2、3年生存率为75.6%(34/45),33.3%(15/45),17.8%(8/45)。经皮股动脉导管药盒植入术的并发症包括1例切口感染及切口延迟愈合,4例PCS堵塞和1例留置导管尖移位。所有并发症经适当处理后无严重后遗症。结论经皮股动脉导管药盒系统植入术对介入治疗肝细胞性肝癌是1种安全有效技术。Objective To evaluate the clinical efficacy and complication of percutaneous intra-arterial femoral port-catheter system（PCS） for interventional treatment for hepatocellular carcinoma. Methods From January 1999 to March 2001,45 patients with hepatocellular carcinoma were treated by using chemotherapy and lipiodol embolization via PCS. The clinical efficacy and complication were retrospectively analyzed. Results The overall response rate was 66.7% （30/45）. The 1-year, 2-year, 3-year overall survival rate was 75.6% （34/45）, 33.3% （15/45）, 17.8% （8/45）. The complication of percutaneous intraarterial femoral portcatheter system implatation included lpatients with incision infection delayed healing and wound dehiscence; 4 patients with indwelling catheter blockage; 1 patient with migrating of catheter tip. Most of these cases were recovered after appropriate management without any serious outcomes. Conclusion The technique of percutaneous intra-arterial femoral port-catheter system implatation for interventional treatment for hepatocellular carcinoma is safe and reliable.

关 键 词：介入治疗 导管药盒系统 股动脉 肝细胞性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]